Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of BI 44847 in Different Ethnic Groups
NCT02211950Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2008
- Primary completion
- Dec 2008
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of BI-44847 in type 2 diabetes mellitus (T2DM) (5 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve from 0 to infinity up to 48 hours, Area under the concentration-time curve from 0 to 48 hours and 2 more. Started Oct 2008; status: completed.
02
Drugs
BI-44847
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02211950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02211950.